Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD — NMES  

Acute Exacerbation of COPD Clinical Trial

Official title: Effect of Neuromuscular Electrical Nerve Stimulation on Quadriceps Muscle Strength and Endurance in Patients With Chronic Obstructive Pulmonary Disease

Status Not yet recruiting

Clinical Trial Summary

Chronic Obstructive Pulmonary Disease (COPD) is a respiratory condition that results in a mixture of small airway disease and parenchymal destruction, changes that are characteristic of emphysema. COPD is also characterized by persistent airflow limitation, an aspect which is noted to be a major cause of morbidity and disease burden worldwide. One in every 8 patients who suffer an exacerbation requires to be admitted to the hospital. Due to repercussions that arise both because of the systemic effects of COPD and also the aggravating factors due to the exacerbation, new adjuncts to treatment are being researched. NMES is a non-invasive and non-addictive means of muscle contraction and was introduced as a rehabilitation means post muscle injury, surgery, and eventually in certain diseases and its use in the treatment of patients with COPD is being looked into. This research study shall adopt a quantitative approach. A Randomised Control Trial (RCT) shall be used to investigate the effect of Neuromuscular Electrical Nerve Stimulation on quadriceps muscle strength and endurance. Approximately 103 patients shall be randomly enrolled in the control group and the experimental group. The control group shall receive Physiotherapy as already provided by physiotherapists including chest and mobility exercises. The experimental group shall undergo Physiotherapy with the addition of NMES. To assess the effect of NMES on quadriceps strength and endurance, quadriceps strength shall be tested through the use of a hand-held dynamometer. Endurance shall be tested through a quadriceps endurance test which requires the leg to be extended against a weight corresponding to 70% of the 1 repetition maximum with a pace of 12 movements per minute, a test which will be stopped when the patient can no longer perform the movement despite strong verbal prompting and encouragement and the standardised 1-minute sit-to-stand. All tests are to be conducted before the intervention, hence on admission to the local general hospital and prior discharge to a maximum of 30 days from the date of admission. All tests shall be done in the patients' ward setting. Also, a diagnostic ultrasound scan of this group of muscles shall be performed upon admission and before discharge by a consultant radiologist at the radiology department. The Borg scale shall be used to assess the shortness of breath of the patients following the 1-minute sit-to-stand.

Clinical Trial Description

Chronic Obstructive Pulmonary Disease (COPD) is a respiratory condition that results in a mixture of small airway disease and parenchymal destruction, changes which are characteristic of emphysema. Research showed that COPD is also characterized by persistent airflow limitation, an aspect which some authors noted to be a major cause of morbidity and disease burden worldwide. One in every 8 patients who suffer an exacerbation of COPD requires to be admitted to the hospital. Literature also reported that re-admissions following discharge amounted to more than 20% within the first 20 days and continued to increase to approximately 33% within the first 90 days post-discharge from the hospital. Therefore, given that a high portion of patients will require further hospitalisations, this will impose a financial burden on the health care systems. It emphasized the fact that apart from the pulmonary changes and respiratory impairments, patients diagnosed with COPD have systemic morphological and biomechanical changes. Morphological changes include a reduction in the cross-sectional area and a reduction in muscle mass. Biochemical changes are primarily due to long-term use of steroids and Chronic Systemic Inflammatory Syndrome (CSIS). Given such changes, more energy is required during activities of daily living (ADLs) by such patients, resulting in shortness of breath (SOB) following minimal exercises. Due to muscle dysfunction, these patients develop physical deconditioning which is one of the primary symptoms reported. The primary cause of this relates to the ventilatory limitations present. The severity of the condition and related pathophysiological changes also predict the level of exercise tolerance, with a worse condition resulting in increased levels of muscle atrophy, weakness affecting mostly the lower limbs, and poor oxidative capacity. In 2008, it was noted that the majority of patients with a severe form of COPD were so frail or dyspnoeic, making them unable to tolerate sufficient exercise training intensities required to improve their level of physical activity. Such patients were noted to become dyspnoeic following low-intensity physical activity, resulting in a decreased physical activity to control their SOB, with ultimately one-third of these patients exhibiting quadriceps muscle weakness related to immobility and decreased exercise tolerance. Deterioration in muscle strength was the most commonly reported symptom characteristic of limb muscle dysfunction in people with COPD. In 2014, Mathur et al. noted that the occurrence of COPD patients experiencing early termination of exercise related to leg fatigue was approximately 40% more common than patients rating of SOB. A further 30% of the population sample reported equal leg fatigue and dyspnoea. The higher the number of patients with COPD that become immobile, the more muscle mass is lost, and this loss continues to increase in periods of hospitalisation due to an exacerbation. Gosselink and Langer (2016) stated that immobility and inactivity both considerably contributed to muscle atrophy via the term "mechanical silencing". Fear and immobility during and or exactly after an AECOPD also play a huge role in quadriceps strength. The deterioration in physical activity and muscle strength, primarily quadriceps muscle was noted throughout the course of the disease. It is further evident during the hospitalisation phase due to an acute onset of COPD. Research has now changed its course of direction to find new methods and modalities which can assist COPD patients in maintaining some form of muscle activity even during their weakest days. Neuromuscular Electrical Nerve Stimulation (NMES) has been the most researched modality in combination with Pulmonary Rehabilitation (PR) with a variation in parameters use and duration of application. NMES is a non-invasive means of muscle contraction and was introduced as a way for rehabilitation post muscle injury, surgery and eventually in certain diseases. NMES involves placing a conductive pad over the muscle and uses an intermittent electrical current to trigger action potentials and activate the intramuscular nerve branches and muscle fibres to generate a strong muscle contraction. It is a device which is self-administered, does not require supervision and carries a low metabolic load, providing an acceptable therapy for patients with a high symptom burden. Therefore, after reviewing the above-mentioned gaps in literature where NMES is emerging as a promising modality in assisting patients with an exacerbating episode of COPD. Methodology To answer the research question stated above, a Randomised Control Trial (RCT) type of study design shall be adopted. An RCT is a study where participants are randomly assigned to an experimental and control group. As the study is conducted, the only expected difference between the control and experimental groups in a randomized controlled trial is the outcome variable being studied. This is important to approximate a controlled experiment, decrease bias and also improve statistical efficiency. In this research study, quadriceps strength, and endurance are the primary outcome variables. With the CAT and changes in rectus femoris, thickness and width through diagnostic ultrasound shall act as the secondary outcome measures. Data collection shall focus on measuring quadriceps strength and assessing for structural changes, changes in the number of sit-to-stand repetitions for a duration of 1 minute and changes in the COPD Assessment Test (CAT) score. Patients shall be asked to carry out these tests on admission and on the same day of discharge from the hospital. A quantitative analysis will follow to determine whether NMES affected quadriceps muscle strength and endurance during an acute exacerbation of COPD. Concurrently, the same quantitative approach will be used to determine the severity of the patients admitted with an AECOPD to the hospital, alongside the level of anxiety and depression related to the chronic condition. This research study will adopt a randomized-experimental research trial. Patients will be randomly assigned into two groups, the control group and the experimental group through an unpredicted randomised sequence and implementing the sequence that conceals the treatment until the patients are formally assigned to their groups. The control group shall receive the usual physiotherapy treatment currently offered to these patients in the ward setting by physiotherapists responsible for their care. Participants shall be given a unique code before the commencement of the study. All must have been previously diagnosed with COPD according to the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) criteria which means that patients were presented with a Forced Expiratory Flow in one second (FEV1) of <70% of the predicted value and a Forced Expiratory Flow in one second to Forced Vital Capacity (FEV1: FVC) of <0.70. Intervention All patients enrolled will be randomly assigned into two groups, the control group and the experimental group. Every participant shall be given a code before the commencement of the study. The code will only be known to the researcher and the supervisor, the latter having no access to the computer used for data collection. The control group shall receive the usual physiotherapy treatment in their respective wards. The patients enrolled on the experimental group will have the usual physiotherapy treatment with the addition of NMES throughout their hospital stay. Electrodes shall be placed on the quadriceps group of muscles, bilaterally and concurrently. Muscle stimulation is achieved using a portable stimulator, which can generate electrical pulses. The electrodes must be placed over the motor point of the muscle or muscle group to be stimulated. Amplitude, rate and waveform, which can also be referred to as the stimulus parameters, are adjusted to facilitate quality of movement and contraction without the muscle being fatigued throughout the treatment session (Hultman et al., 1983). NMES is described as an easy-to-use, easy-to-read and comfortable apparatus where the parameters are adjustable to the patient's progression, and programme recognition can be easily used by the patient. These parameters have been chosen based on reports that concluded that a frequency of more than 50Hz stimulates cause a tetanic fusion, thus stimulating muscle contraction. Various other studies also supported such parameters Ethical Considerations Ethical approval was sought and approved by the University of Malta Research Ethics Committee (UREC). Patients will be instructed about the study through verbal and written information letters and consent will be requested. Informed consent will be needed from the participants and will be allowed to quit the research study when desired. All the data that will be collected regarding the patient will only be used for this study. All information gathered before and after the research study will be discarded upon completion. ;

Related Conditions & MeSH terms

• Acute Exacerbation of COPD
• Chronic Obstructive Pulmonary Disease Moderate
• Chronic Obstructive Pulmonary Disease Severe
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

• NCT number: NCT05539547
• Study type: Interventional
• Source: University of Malta
• Contact: Randall Debattista, Physiotherapist
• Phone: +35679951305
• Email: randalldebattista@gmail.com
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: October 1, 2022
• Completion date: May 30, 2024